Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1/2 5Phase 3 4Phase 2/3 2Phase 1 2

Status

Completed 3Recruiting 2

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Gynecologic 1

Conditions

Colorectal Neoplasms 36Pancreatic Neoplasms 26Rectal Neoplasms 15Esophageal Neoplasms 13Colonic Neoplasms 12Stomach Neoplasms 11Squamous Cell Carcinoma of Head and Neck 11Neoplasm Metastasis 8Gastrointestinal Neoplasms 8Esophageal Squamous Cell Carcinoma 7Adenocarcinoma Of Esophagus 7Neoplasms 6Head and Neck Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Non-Small-Cell Lung 5Biliary Tract Neoplasms 5Carcinoma, Hepatocellular 4Advanced Solid Tumors 4Melanoma 3Liver Neoplasms 3Carcinoma, Renal Cell 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Kidney Neoplasms 2Gastrointestinal Diseases 2Endometrial Neoplasms 2Carcinoma 2

Interventions

Gemcitabine 13Cisplatin 10pembrolizumab 7Oxaliplatin 5Leucovorin 5Fluorouracil 5durvalumab 4Paclitaxel 4Nivolumab 3Injections 3Immune Checkpoint Inhibitors 3Capecitabine 3camrelizumab 2Docetaxel 2Cetuximab 2Carboplatin 2130-nm albumin-bound paclitaxel 2tremelimumab 1surufatinib 1spartalizumab 1silmitasertib 1regorafenib 1pertuzumab 1manganese chloride 1lenvatinib 1irinotecan sucrosofate 1folfirinox 1devimistat 1derazantinib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Biliary Tract Neoplasms × Fluorouracil × Clear all
NCT03785873 2026-02-13

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

University of Michigan Rogel Cancer Center

Phase 1/2 Completed
34 enrolled 13 charts
Gastrointestinal

Biliary Tract Neoplasms

NCT06428409 2026-01-22

MK-9999-02A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Colorectal Neoplasms

NCT05482893 2025-11-04

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Phanes Therapeutics

Phase 1/2 Recruiting
258 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT03314935 2025-08-12

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Incyte Corporation

Phase 1/2 Completed
149 enrolled 35 charts
GastrointestinalGynecologic

Biliary Tract Neoplasms, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05116891 2023-07-03

A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors

Cantargia AB

Phase 1/2 Completed
40 enrolled
GastrointestinalThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡